PainReform (PRFX) 20-F 15 Mar 23 2022 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2022 shares
Entity Registrant Name	PAINREFORM LTD
Document Type	20-F
Document Fiscal Period Focus	FY
Document Period End Date	Dec. 31, 2022
Entity Well-known Seasoned Issuer	No
Entity Shell Company	false
Entity Central Index Key	0001801834
Entity Filer Category	Non-accelerated Filer
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Incorporation, State or Country Code	L3
Document Fiscal Year Focus	2022
Entity Emerging Growth Company	true
Entity Voluntary Filers	No
Entity File Number	001-39481
Document Annual Report	true
Entity Common Stock, Shares Outstanding	10,634,166
Entity Interactive Data Current	Yes
Trading Symbol	PRFX
Security Exchange Name	NASDAQ
Entity Ex Transition Period	true
Title of 12(b) Security	Ordinary shares, par value NIS 0.03 per share
Entity Address, City or Town	Tel Aviv
Entity Address, Address Line One	65 Yigal Alon St.,
Entity Address, Postal Zip Code	6744316
Entity Address, Country	IL
Document Accounting Standard	U.S. GAAP
Document Registration Statement	false
Document Shell Company Report	false
ICFR Auditor Attestation Flag	false
Document Transition Report	false
Auditor Firm ID	1197
Auditor Location	Tel Aviv, Israel
Auditor Name	Brightman Almagor Zohar & Co
Kesselman & Kesselman [Member]
Auditor Firm ID	1309
Auditor Location	Tel-Aviv, Israel
Auditor Name	Kesselman & Kesselman
Business Contact [Member]
Contact Personnel Email Address	ihadar@painreform.com
Entity Address, City or Town	Tel Aviv
Entity Address, Address Line One	65 Yigal Alon St.
Contact Personnel Name	Ilan Hadar
Entity Address, Postal Zip Code	6744316
Entity Address, Country	IL

BALANCE SHEETS

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 4,096	$ 16,537
Short term deposit	6,085	0
Restricted cash	10	34
Prepaid clinical trial expenses and deferred clinical trial costs	1,728	1,728
Prepaid expenses and other current assets	365	721
Total current assets	12,284	19,020
Property and equipment, net	44	53
Total assets	12,328	19,073
Current liabilities:
Trade payables	209	136
Employees and related liabilities	499	423
Accrued expenses	356	198
Total current liabilities	1,064	757
Non-current liabilities:
Provision for unrecognized tax positions	243	234
Total non-current liabilities	243	234
Total liabilities	1,307	991
Commitments
Shareholders’ Equity:
Ordinary shares, NIS 0.03 par value; Authorized: 26,666,667 shares as of December 31, 2022 and 2021, respectively; Issued and outstanding: 10,634,166 and 10,482,056 shares as of December 31, 2022 and 2021, respectively.	94	94
Additional paid-in capital	43,446	41,715
Accumulated deficit	(32,519)	(23,727)
Total shareholders’ equity	11,021	18,082
Total liabilities and shareholders’ equity	$ 12,328	$ 19,073

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) $ in Thousands	Dec. 31, 2022 ₪ / shares shares	Dec. 31, 2021 ₪ / shares shares
Statement of Financial Position [Abstract]
Ordinary shares, par value (in New Shekels per share) | (per share)	₪ 0.03	₪ 0.03
Ordinary shares, shares authorized	26,666,667
Ordinary shares, shares issued	10,634,166	10,482,056
Ordinary shares, shares outstanding	10,634,166	10,482,056

STATEMENTS OF COMPREHENSIVE LOS

STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating expenses:
Research and development expenses	$ (4,422)	$ (2,860)	$ (354)
General and administrative expenses	(4,447)	(4,348)	(1,317)
Operating loss	(8,869)	(7,208)	(1,671)
Interest expenses	0	0	(987)
Other financial income (expenses), net	86	(32)	(1,175)
Loss before taxes	(8,783)	(7,240)	(3,833)
Tax expenses	(9)	(6)	(220)
Net loss and comprehensive loss	$ (8,792)	$ (7,246)	$ (4,053)
Basic and diluted net loss per share basic (in dollars per share)	$ (0.82)	$ (0.74)	$ (1.25)
Basic and diluted net loss per share diluted (in dollars per share)	$ (0.82)	$ (0.74)	$ (1.25)
Shares of ordinary share and restricted shares used in computing basic net loss per share	10,661,170	9,812,234	3,243,943
Shares of ordinary share and restricted shares used in computing diluted net loss per share	10,661,170	9,812,234	3,243,943

STATEMENTS OF CHANGES IN CONVER

STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Convertible preferred shares (Temporary equity) [Member]	Ordinary shares [Member]	Additional paid-in capital [Member]	Accumulated deficit [Member]	Total
Balance at Dec. 31, 2019	$ 6,621	$ 5	$ 180	$ (12,428)	$ (12,243)
Balance, shares (in Shares) at Dec. 31, 2019	2,954,267	576,556
Conversion of preferred shares into ordinary shares	$ (6,621)	$ 26	6,595	0	6,621
Conversion of preferred shares into ordinary shares (in Shares)	(2,954,267)	2,954,267
Conversion of convertible notes into ordinary shares	$ 0	$ 25	7,135	0	7,160
Conversion of convertible notes into ordinary shares (in Shares)	0	2,727,214
Share issuance under Initial Public Offering, net	$ 0	$ 22	17,288	0	17,310
Share issuance under Initial Public Offering, net (in Shares)	0	2,500,000
Equity classification of a derivative warrant liability (Note 6(b))		$ 0	1,552	0	1,552
Share-based compensation to employees	$ 0	$ 0	38	0	38
Share-based compensation to employees, shares ( in Shares)	0	0
Share-based compensation to service providers	$ 0	$ 0	202	0	202
Share-based compensation to service providers, shares	0	0
Operating lease provided by controlling shareholder	$ 0	$ 0	33	0	33
Net loss and comprehensive loss	0	0	0	(4,053)	(4,053)
Balance at Dec. 31, 2020	$ 0	$ 78	33,023	(16,481)	16,620
Balance, shares (in Shares) at Dec. 31, 2020	0	8,758,037
Share-based compensation to employees and directors		$ 0	812	0	812
Share-based compensation to employees and directors (in shares)		0
Share-based compensation to service providers		$ 0	412	0	412
Share-based compensation to service providers, shares		0
Shares and warrants issuance - Private Investment in Public Equity ("PIPE"), net		$ 12	5,542	0	5,554
Shares and warrants issuance - Private Investment in Public Equity ("PIPE"), net (in shares)		1,304,346
Exercise of warrants		$ 4	1,926	0	1,930
Exercise of warrants (in shares)		419,673
Net loss and comprehensive loss		$ 0	0	(7,246)	(7,246)
Balance at Dec. 31, 2021		$ 94	41,715	(23,727)	18,082
Balance, shares (in Shares) at Dec. 31, 2021		10,482,056
Share-based compensation to employees and directors		$ 0	1,389	0	1,389
Share-based compensation to employees and directors (in shares)		0
Share-based compensation to service providers		$ 0	342	0	342
Share-based compensation to service providers, shares		0
Share issuance to service providers		$ 0	0	0
Share issuance to service providers (shares)		152,110
Net loss and comprehensive loss		$ 0	0	(8,792)	(8,792)
Balance at Dec. 31, 2022		$ 94	$ 43,446	$ (32,519)	$ 11,021
Balance, shares (in Shares) at Dec. 31, 2022		10,634,166

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (8,792)	$ (7,246)	$ (4,053)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	15	7		[1]
Operating lease provided by controlling shareholder	0	0	33
Share-based compensation to employees	1,389	812	38
Share-based compensation to service providers	342	412	202
Interest expense and amortization of discount on convertible notes	0	0	987
Interest income	(85)	0	0
Revaluation of derivative warrant liability	0	0	1,105
Changes in operating assets and liabilities::
Prepaid expenses and other current assets	356	(348)	(1,884)
Trade payables	73	(585)	720
Employees, related liabilities and accrued expenses	243	395	295
Net cash used in operating activities	(6,459)	(6,553)	(2,557)
Cash flows from investing activities
Purchase of property and equipment	(6)	(50)	(10)
Purchase of short-term deposit	(6,000)	0	0
Net cash used in investing activities	(6,006)	(50)	(10)
Cash flows from financing activities
Proceeds from exercise of warrants	0	1,930	0
under Private Investment in Public Equity	0	6,000	0
Issuance costs	0	(446)	0
Proceeds from issuance of ordinary shares under Initial Public Offering, net	0	0	17,310
Net cash provided by financing activities	0	7,484	17,310
Net increase (decrease) in cash, cash equivalents and restricted cash	(12,465)	881	14,743
Cash, cash equivalents and restricted cash at the beginning of the year	16,571	15,690	947
Cash, cash equivalents and restricted cash at the end of the year	4,106	16,571	15,690
Supplemental cash flow information:
Cash and cash equivalents	4,096	16,537	15,677
Restricted cash	10	34	13
Cash, cash equivalents and restricted cash at the end of the year	$ 4,106	$ 16,571	$ 15,690
[1]Represents amount less than $1

GENERAL

GENERAL	12 Months Ended
	Dec. 31, 2022
Compensation Related Costs [Abstract]
GENERAL	NOTE 1:- GENERAL a. PainReform Ltd. ("the Company") was incorporated and started business operations in November 2007. The Company is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. The Company’s proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates. b. Liquidity Since its inception, the Company has devoted substantially all its efforts to research and development, clinical trials, and capital raising activities. The Company is still in its development and clinical stage and has not yet generated revenues. The Company has incurred significant losses and negative cash flows from operations and incurred losses of $8,792, $7,246 and $4,053 for the years ended December 31, 2022, 2021 and 2020, respectively. During the years ended December 31, 2022, 2021 and 2020, the Company had negative operating cash outflows of $6,459, $6,553, and $2,557, respectively. As of December 31, 2022, the Company’s accumulated deficit was $32,519. The Company has funded its operations to date primarily through equity financing and has cash on hand (including short term deposits and restricted cash) of $10,191 as of December 31, 2022. The Company expects to continue incurring losses, and negative cash flows from operations until its product, PRF-110, reaches commercial profitability. As a result of the initiation of the Company's Phase III clinical trial in March 2023, along with its current cash position, the Company does not have sufficient resources to fund operations until the end of its phase III study, nor to continue as a going concern for at least one year from the issuance date of these financial statements. Management's plans include continued raising capital through sale of additional equity securities, debt or capital inflows from strategic partnerships. There are no assurances, however, that the Company's will successfully obtain the level of financing needed for its operations. If the Company is unsuccessful in raising capital, it may need to reduce activities, curtail, or abandon some or all of its operations, which could materially harm the Company’s business, financial condition and results of operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business and do not include any adjustments that might result from the outcome of this uncertainty. On March 11, 2021, the Company closed a private placement of 1,304,346 ordinary shares, par value NIS 0.03 per share (the “Ordinary Shares”) and accompanying warrants to purchase an aggregate of up to 652,173 Ordinary Shares at a combined purchase price of $4.60 per share and accompanying warrant resulting in gross proceeds of $6,000. The warrants are exercisable immediately at an exercise price of $4.60 per share and expire five and a half years from the issuance date. On July 22, 2021, the Company issued 419,673 Ordinary Shares upon exercise of warrants for consideration totalling $1,930 (Note 10). c. The Company effected a 1-for-3 reverse split of the Company’s Ordinary Shares and convertible preferred shares on July 6, 2020. All issued and outstanding Ordinary Shares and convertible preferred share and related per share amounts contained in these financial statements have been retroactively adjusted to reflect this reverse share split for all periods presented. On September 3, 2020, the Company closed its initial public offering ("IPO") of 2,500,000 units at a price of $8.00 per unit. Each unit consisted of one Ordinary Share and one warrant to purchase one Ordinary Share. The ordinary shares and warrants were immediately separable from the units and were issued separately. The warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $8.80 per share. On October 5, 2020, the underwriters exercised their over-allotment option and were issued warrants to purchase 375,000 Ordinary Shares in return for proceeds of $3 per share. These warrants also expire five years from the date of issuance and have an exercise price of $8.80 per share. The Company received gross proceeds of approximately $20,000 (net proceeds of approximately $17.3 million after deducting underwriting discounts and commissions and other offering expenses). d. In December 2019, an outbreak of a novel coronavirus disease, or COVID-19, was first identified and began to spread across the globe and, in March 2020, the World Health Organization declared it a pandemic. This contagious disease has spread across the globe and is impacting economic activity and financial markets worldwide. While the spread of COVID-19 has not yet materially impacted the Company's operations nor affected management’s judgment and assumptions at the end of 2022, 2021 and 2020, the Company's previously anticipated timeline for its planned trials has been impacted by COVID-19, particularly in the manufacturing process. The extent to which COVID-19 continues to impact the Company's development efforts will depend on future developments, which are highly uncertain and cannot be predicted, including the actions to contain COVID-19 or treat its impact, among others. e. U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine. In February 2022, Russia launched a full-scale military invasion of Ukraine. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets. Additionally, Russia’s prior annexation of Crimea, recent recognition of two separatist republics in the Donetsk and Luhansk regions of Ukraine and subsequent military interventions in Ukraine have led to sanctions and other penalties being levied by the United States, European Union and other countries against Russia, Belarus, the Crimea Region of Ukraine, the so-called Donetsk People’s Republic, and the so-called Luhansk People’s Republic, including agreement to remove certain Russian financial institutions from the Society for Worldwide Interbank Financial Telecommunication (SWIFT) payment system. Additional potential sanctions and penalties have also been proposed and/or threatened. Russian military actions and the resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets, potentially making it more difficult for us to obtain additional funds. Any of the abovementioned factors could affect our business, prospects, financial condition, and operating results. The extent and duration of the military action, sanctions and resulting market disruptions are impossible to predict. f. The continued listing standards of Nasdaq require, among other things, that the minimum bid price of a listed company’s stock be at or above $1.00. If the closing minimum bid price is below $1.00 for a period of more than 30 consecutive trading days, the listed company will fail to comply with Nasdaq’s listing rules and, if it does not regain compliance within the grace period, will be subject to delisting. As previously reported, on August 16, 2022, the Company received a notice from the Nasdaq Listing Qualifications Department notifying us that for 30 consecutive trading days, the bid price of our ordinary shares had closed below the minimum $1.00 per share requirement. In accordance with Nasdaq’s listing rules, the Company were afforded a grace period of 180 calendar days, or until February 6, 2023, to regain compliance with the bid price requirement. In order to regain compliance, the bid price of ordinary shares must close at a price of at least $1.00 per share for a minimum of 10 consecutive trading days. On February 7, 2023, Nasdaq notified us that the Company were eligible for a second 180 day compliance period. If at anytime before August 7, 2023, the bid price of our ordinary shares closes at or above $1 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the listing standards of Nasdaq. If the Company fail to regain compliance by August 7, 2023, our ordinary shares will be subject to delisting. g. The Company report our financial results in U.S. dollars. A portion of research and development and general and administrative expenses of our Israeli operations are incurred in New Israeli Shekel ("NIS"). As a result, the Company is exposed to exchange rate risks that may materially and adversely affect our financial results. If the NIS appreciates against the U.S. dollar, or if the value of the NIS decline against the U.S. dollar, at a time when the rate of inflation in the cost of Israeli goods and services exceed the rate of decline in the relative value of the NIS, then the U.S. dollar-denominated cost of our operations in Israel would increase and our results of operations could be materially and adversely affected. Inflation in Israel compounds the adverse impact of a devaluation of the NIS against the U.S. dollar by further increasing the amount of our Israeli expenses. Israeli inflation may also (in the future) outweigh the positive effect of any appreciation of the U.S. dollar relative to the NIS, if, and to the extent that, it outpaces such appreciation or precedes such appreciation. The Israeli rate of inflation did not have a material adverse effect on our financial condition during 2022 ,2021 and 2020. Given our general lack of currency hedging arrangements to protect us from fluctuations in the exchange rates of the NIS in relation to the U.S. dollar (and/or from inflation of such non-U.S. currencies), the Company may be exposed to material adverse effects from such movements. the Company cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation (if any) of the U.S. dollar against the NIS. h. In April 2022, the Company's board of directors decided to increase the number of reserved Ordinary Shares under the 2019 PainReform Option Plan (the “2019 Plan”) by an additional amount of 1,000,000 Ordinary Shares. As a result of the decision, the Company's option pool increased by an additional 1,000,000 ordinary shares (Note 10).

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES a. Basis of presentation: The financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The significant accounting policies described below have been applied consistently in relation to all the periods presented, unless otherwise stated. b. Use of estimate in preparation of financial statements: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions. Estimates are primarily used for, but not limited to, valuation of share-based compensation, capitalization of software costs, valuation allowance and uncertain tax positions. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. c. Financial statements in United States dollars: The Company’s functional currency is the U.S. dollar (“dollar” or “$”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non-U.S. dollar currencies are translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S. dollar transactions and other items in the statements of income (indicated below), the following exchange rates are used: (i) for transactions - exchange rates at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation) - historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses, as appropriate. d. Cash and cash equivalents: Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition. e. Short term deposit: Bank deposits with original maturity dates of more than three months but at balance sheet date are less than one year are included in short-term deposits. The fair value of bank deposits approximates the carrying value since they bear interest at rates close to the prevailing market rates. f. Restricted cash: As of December 31, 2022 and 2021, the Company’s restricted cash consisted of immaterial bank deposits that were denominated in NIS. Restricted deposits are presented at cost including accrued interest. These bank deposits are used as securities for the Company's credit cards. g. Fair Value Measurements: The carrying values of Company’s financial assets and liabilities, including cash and cash equivalents, restricted cash, other current assets, trade payables and other accounts payable approximate their fair value due to the short-term maturity of these instruments. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value in the financial statements are categorized as follows: Level 1 Level 2 Level 3 As of December 31, 2022, and 2021 no assets or liabilities are measured in fair value. h. Property and equipment, net: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers, software and electronic equipment 33 Furniture and office equipment 7 i. Research and development expenses: Research and development costs include costs of payroll and related expenses of employees, subcontractors and consultants and other costs related to the Company's operation of its planned clinical trials. Research and development expenses are charged to the statements of comprehensive loss as incurred. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources its clinical trial activities utilizing external entities such as clinical research organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical trials. Clinical trial costs are expensed as incurred. j. Employee severance benefits: The Company is required to make severance payments upon dismissal of an Israeli employee or upon termination of employment in certain circumstances. In accordance with the current employment terms with all of its employees (Section 14 of the Israeli Severance Pay Law, 1963) located in Israel, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee’s full retirement benefit and severance obligation. The Company is relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected on the Company’s balance sheet, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies. The amounts of severance payment expenses were $60, $58 and $13 for the years ended December 31, 2022, 2021 and 2020, respectively. k. Legal and other contingencies: Certain conditions may exist as of the date of the financial statements, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management assesses such contingent liabilities, if any, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. Management applies the guidance in ASC 450-20, “Loss Contingencies” when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be reasonable estimated, then the estimated liability is recorded as accrued expenses in the Company’s financial statements. Legal costs incurred in connection with loss contingencies are expensed as incurred. l. Income taxes: The Company accounts for income taxes in accordance with ASC 740, “Income Taxes”. ASC 740 prescribes the use of the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all the deferred tax assets will not be realized, based on the weight of available positive and negative evidence. As of December 31, 2022, and 2021, the Company had a full valuation allowance on its deferred tax assets. Deferred tax liabilities and assets are classified as non-current in accordance with ASU 2015‑17. The Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax positions as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement. As of December 31, 2022 and 2021, the total gross amount of provision for unrecognized tax positions was $243 and $234, respectively (Note 7f). The Company recognizes interest and penalties, if any, related to unrecognized tax positions in tax expenses and exchange differences in financial expense. m. Concentrations of credit risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and restricted cash. Cash and cash equivalents and restricted cash are invested in a major bank in Israel and the United States. Management believes that the banks that hold the Company’s cash, cash equivalent and restricted cash are financially sound and, accordingly, minimal credit risk exists with respect to this cash, cash equivalent and restricted cash. The Company relies, and expects to continue to rely, on a single supplier to manufacture supplies and raw materials for its clinical trial. This clinical trial could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials. n. Convertible notes: Proceeds from the sale of notes with a conversion feature are allocated to equity based on the intrinsic value of such conversion feature (if any) in accordance with ASC 470-20 “Debt with Conversion and Other Options”, with a corresponding discount on the notes recorded in liabilities which is amortized in finance expense over the term of the notes. Convertible notes with convertible features that are determined to not be beneficial are allocated entirely to liabilities. o. Derivative warrant liability Financial equity instruments that do not meet the US GAAP criteria for equity classification are classified as a liability at fair value and are adjusted to fair value at each reporting period. Changes in fair value are recognized in the Company’s statements of comprehensive loss in accordance with ASC 815, “Accounting for Derivative Financial Instruments”. p. Basic and diluted loss per share: Basic loss per share is computed on the basis of the net loss for the period divided by the weighted average number of Ordinary Shares and vested Ordinary Shares issuable for little or no further consideration outstanding during the period. Diluted loss per share is based upon the weighted average number of ordinary shares and of potential Ordinary Shares outstanding when dilutive. Potential Ordinary Shares include outstanding stock options, restricted shares and warrants, which are included under the treasury stock method when dilutive. For the years ended December 31, 2022, 2021 and 2020, all outstanding share options, restricted shares, convertible notes, and warrants have been excluded from the calculation of the diluted net loss per share as all such securities are anti-dilutive for all years presented. The loss and the weighted average number of shares used in computing basic and diluted net loss per share is as follows: Year ended 2022 2021 2020 Numerator: Net loss applicable to shareholders of ordinary shares $ (8,792 ) $ (7,246 ) $ (4,053 ) Denominator: Shares of Ordinary Share and restricted shares used in computing basic and diluted net loss per share 10,661,170 9,812,234 3,243,943 Net loss per share of ordinary share, basic and diluted $ (0.82 ) $ (0.74 ) $ (1.25 ) q. Share-based compensation: Share-based compensation to employees and consultants is accounted for in accordance with ASC 718, “Compensation - Share Compensation” (“ASC 718”), which requires estimation of the fair value of share-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service period using the strait line method. The Company has elected to recognize forfeitures, as incurred. The Company grants share (“Share Based Compensation”) to its employees, officers, directors, and non-employees in consideration for services rendered (Note 10). The Company accounts for Share-Based Compensation awards classified as equity awards using the grant-date fair value method. The fair value at grant-date of the issued equity award is recognized as an expense on a straight-line basis over the requisite service period. The fair value of each share option granted is estimated using the Black-Scholes option pricing model, which requires a number of assumptions, of which the most significant are the expected share price, volatility, and the expected option term. Expected volatility was calculated based on comparable public companies in the same industry. The expected share option term is calculated for share options granted using the “simplified” method when the required conditions are met. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The expected dividend yield assumption is based on the Company’s historical experience and expectation of no future dividend pay outs. The Company has historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future. The Company elected to recognize Share-Based Compensation cost for awards with only service conditions that have a graded vesting schedule using the straight-line method based on the multiple-option award approach. r. Deferred offering costs The Company capitalizes certain legal and other third-party fees that are directly related to the Company’s in-process equity financings until such financings are consummated. After the consummation of such equity financings, these costs are recorded as a reduction of the respective gross proceeds. Should a planned equity financing be abandoned, terminated, or significantly delayed, the deferred offering costs are written off to operating expenses. As of December 31, 2022 and 2021, there were no deferred offering costs. s. Segment Reporting The Company has one operating and reportable segment. An operating segment is defined as a component that engages in business activities whose operating results are reviewed by the chief operating decision maker, who is the Company’s Chief Executive Officer, for the purpose of assessing performance and allocating resources and for which discrete financial information is available. t. Leases In accordance with Accounting Standards Codification (“ASC”) 842, Leases, the Company determines whether an arrangement is or contains a lease at the inception of the arrangement and whether such a lease is classified as a financing lease or operating lease at the commencement date of the lease. The Company elected not to recognize the right-of-use assets and lease liabilities for short-term leases which it defines as leases with lease terms. The company defines a short-term lease if a lease has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. All of the Company's leases are classified as short-term. Lease expense for lease payments is recognized on a straight-line basis over the lease term in general and administrative (Note 8a). u. Recently adopted accounting pronouncement In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. The Company adopted ASU 2020-06 on January 1, 2022 and it did not have a material impact on the Company’s financial statements and disclosures. v. Recently Issued Accounting Pronouncements Not Yet Adopted Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	12 Months Ended
	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 3:- PREPAID EXPENSES AND OTHER CURRENT ASSETS December 31, 2022 2021 Receivables from governmental authorities $ 55 $ 218 Prepaid expenses 310 473 Other - 30 $ 365 $ 721

ACCURUED EXPENSES

ACCURUED EXPENSES	12 Months Ended
	Dec. 31, 2022
Accrued Liabilities [Abstract]
ACCURUED EXPENSES	NOTE 4:- ACCURUED EXPENSES December 31, 2022 2021 Directors’ fees $ 33 $ 46 Manufacturing expenses 168 13 Advisors and legal expenses 155 139 $ 356 $ 198

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 5:- FAIR VALUE MEASUREMENTS During the year ended December 31, 2019, the Company issued warrants related to its convertible notes (refer to Note 6(b)). As of December 31, 2019, the warrants did not meet the US GAAP criteria for equity classification, and accordingly were classified as a derivative warrant liability and were measured at fair value on the issuance date and as of December 31, 2019, as well as through the date of consummation of the IPO, with changes in fair value recognized as financial expenses in the statements of comprehensive loss. On September 3, 2020, upon consummation of the IPO, the exercise price of the warrants and the number of shares to be issued upon exercise of the warrants were fixed (refer to Note 6(b)), such that they met the criteria for equity classification under US GAAP. Accordingly, the derivative warrant liability was classified to equity as of such date. A summary of significant unobservable inputs (Level 3 inputs) used in measuring the fair value of these warrants is as follows: September 3, December 31 2020 2019 Exercise price $ 6.72-$8.80 $ 2.55-$4.74 Expected volatility 72.29 % 72.29 % Risk free rate 0.22 % 1.5-1.67 % Expected life (years) 3.98-5 4.65-5 Dividend yield - -

CONVERTIBLE NOTES

CONVERTIBLE NOTES	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
CONVERTIBLE NOTES	NOTE 6:- CONVERTIBLE NOTES a. From 2014 until 2019, the Company issued convertible notes in the total principal amount of $4,417 to existing shareholders. The Company recorded interest expense amounting to $271 and $379 for the years ended December 31, 2020 and 2019, respectively. Concurrent with the closing of the IPO, all of the Company’s convertible notes (inclusive of accrued interest on all outstanding notes) were converted into 2,415,022 units (consisting of one Ordinary Share and one warrant to purchase one Ordinary Share). b. In August and December 2019, the Company issued 14.2 units of convertible notes (the “2019 Convertible Notes”) and warrants. Each unit consisted of one convertible note and one warrant. In consideration for the units issued the Company received a total amount of $1,420 (representing a consideration of $100 per unit), after giving effect to a 10% discount. On September 3, 2020, upon consummation of the IPO, the outstanding balance of the 2019 Convertible Notes was converted into 312,170 units, each consisting of one Ordinary Share and one warrant to purchase one Ordinary Share, exercisable immediately, at an exercise price of $8.80 and with an expiry date of 5 years from the IPO closing date. Additionally, on the IPO consummation date, the amount and exercise price of the warrants originally granted in August and December 2019, was fixed at 297,589 warrants and at an exercise price of $6.72, each exercisable into a single unit (refer to Note 1(c)), consisting of one Ordinary Share and one warrant to purchase one Ordinary Shares, exercisable through September 3, 2025, at an exercise price of $8.80. Accordingly, since the warrants met the criteria of equity classification, the respective derivative warrant liability, was classified in equity (refer to note 5). c. On December 9, 2019, in connection with the 2019 Convertible Notes, the Company issued to the placement agent in the offering described above warrants (the “Agents' Warrants”) to purchase an aggregate of 55,785 Ordinary Shares, or units (refer to Note 6(b)), at an exercise price of $6.72 per unit. Each unit consists of one ordinary share and one warrant to purchase one Ordinary Share, exercisable through September 3, 2025, at an exercise price of $8.80. The Agents' Warrants expire on December 8, 2024. As a result of the issuance of the Agents' Warrants, the Company recorded a discount on the convertible note, which was amortized as financial expense amounting to $65 for the year ended December 31, 2020.

TAXES ON INCOME

TAXES ON INCOME	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
TAXES ON INCOME	NOTE 7:- TAXES ON INCOME a. Tax rates applicable to the Company: Taxable income of the Company is subject to the Israeli Corporate tax rate which was 23% for the years ended December 31, 2022, 2021 and 2020. b. Net operating loss carry forward: As of December 31, 2022, and 2021, the Company had net operating loss carry forwards for Israeli income tax purposes of approximately $19,695 and $19,261, respectively. Net operating loss carry forwards in Israel may be carried forward indefinitely and offset against future taxable income. c. As of December 31, 2022, the Company had final tax assessments for tax years prior to and including the tax year ended December 31, 2016. d. Deferred income taxes: Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows: December 31, 2022 2021 Net operating loss carry forward $ 4,530 $ 4,434 Research and development expenses 812 463 Other 34 21 Less: Valuation allowance (5,376 ) (4,918 ) Net deferred tax asset $ - $ - In assessing the realization of deferred tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences are deductible and net operating losses are utilized. Based on consideration of these factors, the Company recorded a full valuation allowance on December 31, 2022, and 2021. e. Reconciliation of theoretical tax expenses to actual expenses The primary difference between the statutory tax rate of the Company and the effective rate results virtually from the changes in valuation allowance in respect of carry forward tax losses, share based compensation expenses and research and development expenses due to the uncertainty of the realization of such tax benefits. f. Uncertain tax positions: A reconciliation of the opening and closing amounts of total unrecognized tax benefits is as follows: December 31, 2022 2021 2020 Opening balance $ 234 $ 220 $ - Tax positions taken in the current year - 217 Interest and Exchange difference 9 14 3 Closing balance $ 243 $ 234 $ 220 The balance of total unrecognized tax position as of December 31, 2022, 2021 and 2020 is $243, $234, $220 respectively, which, if recognized, would affect the effective tax rate in the Company's statements of comprehensive loss. The Company recognizes interest and penalties, if any, related to unrecognized tax positions in tax expenses and exchange differences in financial expense. The accrued interest and exchange difference related to uncertain tax positions and the expenses recognized during the year ended December 31, 2022, 2021 and 2020 is $9, $14, $3 respectively.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8:- COMMITMENTS: a. During the year ended December 31, 2020, the Company was party to a lease agreement with a related party for an annual fee of $33. As of December 31, 2020, the lease agreement with the related party was terminated. On December 10, 2020, the Company entered into a new rental agreement with an un-related party for a period of twelve months starting on January 1, 2021, with an extension option for an additional twelve months, for an annual rental fee of $20. As of December 31, 2021, the agreement was terminated. On July 26, 2021, the Company engaged in a new rental agreement for a period of twelve months starting on August 15, 2021. In August 2022, the company extended the lease for an additional 12 months up to August 2023. The company has an extension option for an additional twelve months subject to the Company's prior notice. The Company is not reasonably certain to exercise this extension option. The annual rent is $68. b. On November 13, 2020, and December 3, 2020, the Company entered into a Master Clinical Research Organization Agreement (the “First Agreement”) and a Master Clinical Trial Agreement (the “Second Agreement”) with Lotus Clinical Research (“Lotus”) as the Company's clinical research organization. According to the agreements Lotus will serve as the clinical research organization for the Company's planned Phase 3 trials of PRF-110, which are expected to commence in March 2023 and to take place during the years 2023 - 2024. Under the First Agreement, the Company is obligated to pay an accumulated amount of approximately $2,907 based upon a milestone completion and under the Second Agreement an accumulated amount of approximately $7,107 based upon actual number of evaluable subjects. During the fourth quarter of 2022 and throughout the first quarter of 2023 the company and the CRO negotiated the term of the first and the second agreements and mutually agreed to update the total milestone completion payment to $5,568 and to update the payment for the actual number of evaluable subject to $8,636. As of December 31, 2022, and 2021, the Company accounted for the amounts of $1,728 as prepaid clinical trial expense and recorded $1,110 and $145 as clinical trials expenses in 2022 and 2021, respectively. No expenses were recorded in 2020.

TEMPORARY EQUITY

TEMPORARY EQUITY	12 Months Ended
	Dec. 31, 2022
Temporary Equity Disclosure [Abstract]
TEMPORARY EQUITY	NOTE 9:- TEMPORARY EQUITY Convertible Preferred Shares Convertible preferred shares consisted of the following: Convertible Preferred Shares - Series A Shares Shares Carrying Liquidation As of December 31, 2019 18,300,000 2,954,267 $ 6,621 $ 15,250 The preferred shares conferred upon their holders all rights accruing to holders of Ordinary Shares in the Company, and, in addition, the rights, preferences and privileges granted to the preferred shares as follows. On September 3, 2020, upon consummation of the IPO, all of the Company’s outstanding convertible preferred shares were converted into 2,954,267 Ordinary Shares.

SHAREHOLDERS' EQUITY

SHAREHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
SHAREHOLDERS' EQUITY	NOTE 10:- SHAREHOLDERS’ EQUITY a. Ordinary shares The Ordinary Shares confer upon their holders the right to participate and vote in general shareholder meetings of the Company and to share in the distribution of dividends, if any, declared by the Company, and rights to receive a distribution of assets upon liquidation. b. Shares activity: 1. On July 6, 2020, pursuant to the Company’s shareholders approval, the Company effected a 3-for-1 reverse split of the Company’s Ordinary Shares and convertible preferred shares. 2. In addition, on the IPO closing date, the Company granted to the underwriters of the IPO warrants to purchase 125,000 Ordinary Shares, which equals five percent (5%) of the total number of units sold in the IPO, excluding the over-allotment option, at an exercise price $10.00 per share. The warrants (the “Underwriters’ Warrants”) contain a cashless exercise feature. The Underwriters’ Warrants are exercisable for Ordinary Shares on a cash or cashless basis at an exercise price of $10.00 per Ordinary Share which price reflects 125% of the public offering price of the units issued in the offering. The Underwriters’ Warrants are exercisable following twelve (12) months after the effective date of the registration statement relating to the IPO and expire five (5) years after such effective date. The Underwriters’ Warrants are non-transferable. As part of the IPO, the Company granted the IPO underwriters an over-allotment to purchase up to 375,000 additional warrants at the public offering price of $0.01, less the underwriting discounts and commissions. On October 5, 2020 the underwriters exercised their over-allotment option and were issued warrants to purchase 375,000 Ordinary Shares at a net amount of $3 per share. The warrants are exercisable through September 3, 2025, at an exercise price of $8.80. 3. On March 11, 2021, the Company issued to certain institutional investors (the “Purchasers”) 1,304,346 Ordinary Shares and warrants to purchase up to an aggregate of 652,173 ordinary shares at a combined purchase price of $4.60 per Ordinary Share and accompanying warrant in a Private Investment in Public Equity ("Private placement") pursuant to a securities purchase agreement. The private placement resulted in gross proceeds of approximately $6,000. The Company received net amount of $5,554 less issuance costs. On July 22, 2021, as a result of an exercise of warrants to purchase 419,673 shares held by one of the Purchasers, the Company received gross proceeds of $1,930. In connection with the private placement, the Company also entered into a Registration Rights Agreement, dated as of March 8, 2021, with the Purchasers (the “Registration Rights Agreement”). Pursuant to the Registration Rights Agreement, the Company filed a registration statement (the “Registration Statement”), with the SEC to register the resale of the ordinary shares and the Ordinary Shares issuable upon exercise of the warrants. The Registration Statement was declared effective on April 9, 2021. The Company paid the placement agents of the private placement a cash placement fee equal to $390 and an expense reimbursement of $40. The Company also issued to the placement agents warrants to purchase 52,173 Ordinary Shares, at an exercise price of $5.06 per ordinary share and a term expiring on March 10, 2026. The Company paid a total of approximately $500 in placement agent fees and other expenses. 4. In April 2022, the Company issued 152,110 shares to Crescendo in connection with the first grant (Note 10d.5 and note 13). c. Warrants and warrants units: The following table summarizes the warrants and warrants units outstanding as of December 31, 2022: Type Issuance Date Number of warrants Exercise price Exercisable through August 2019 warrants August 22, 2019 205,268 $6.72 (*) August 22, 2024 December 2019 warrants December 9, 2019 148,106 $6.72 (*) December 8, 2024 Warrants to underwriters September 3, 2020 125,000 $10.00 September 1, 2025 Warrants to underwriters October 5, 2020 375,000 $8.80 September 3, 2025 IPO warrants September 3, 2020 2,812,170 $8.80 September 3, 2025 PIPE warrants March 11, 2021 232,500 $4.60 September 10, 2026 Warrants to PIPE placement agent March 11,2021 52,173 $5.06 March 8, 2026 TOTAL 3,950,217 (*) Each warrant is exercisable into one IPO unit consisting of one share and one IPO warrant with an exercise price of $8.80. d. Share-based compensation: 1. The 2008 Plan On August 7, 2008, the Board of Directors approved the adoption of the 2008 Share Option Plan (the “2008 Plan”). The 2008 Plan has expired, and no additional grants may be made. As a result of the Modification, (A) 667,641 options were cancelled, comprised of (i) 51,166 options that had been granted in September 2019, at an exercise price of $3.34, (ii) 267,296 options that had been granted in November 2020, at an exercise price of $5.74, (iii) 133,652 options granted in January 2021, at an exercise price of $5.74, and (iv) 51,072 options granted in May 2021, at an exercise price of $3.01, and (ii) 164,455 options that had been granted in April 2022 at an exercise price of $1.06 (the “Cancelled Options”), and (B) 988,773 new options had been granted (including 21,268 option granted to a new employee) (the “New Options”). The intrinsic value of share options outstanding and exercisable as of December 31, 2022 was $27. 2. The 2019 Plan On July 2, 2019, the Board of Directors approved the adoption of the 2019 Plan. Under the 2019 Plan, the Company may grant its officers, directors, employees and consultants share options of the Company. Each share option granted shall be exercisable at such times and terms and conditions as the Board of Directors may specify in the applicable share option agreement, provided that no share option will be granted with a term in excess of 10 years. Upon the adoption of the 2019 Plan, the Company reserved for issuance 971,476 ordinary shares. On February 23, 2021, the shareholders of the Company approved the grant of options to purchase an aggregate of 300,000 Ordinary Shares to three current board members, the Chairman of the board of directors and to the Chief Technology Officer (who is also a director). Each was granted with options to purchase 60,000 Ordinary Shares of the Company. The options are exercisable to acquire one Ordinary Share of the Company at an exercise price of $4.50 per share. The options vest on a quarterly basis over thirty-six months, so that 1/12 of the options shall vest on the last day of each three-month period, provided that on such date each of the serving directors and Chief Technology Officer, shall serve in such capacity. The options will expire after ten years from their grant date. In addition, the unrecognized compensation cost as of the date of Modification will be recognized over the vesting period of the new options. As a result, an amount of 50% of the unrecognized compensation cost of the cancelled options were vested immediately in the amount of $454, and the remaining unrecognized compensation cost will be recognized over the remaining vesting period and until December 31, 2022. In April 2022, the Company’s board of directors approved the grant of options to purchase 164,455 Ordinary Shares of the Company to employees. The options were granted under the Company's 2019 plan. The fair value of share options granted was estimated using the Black Scholes option-pricing model, which requires several assumptions, of which the most significant are the expected share price, volatility, and the expected option term. The options vest over a four-year period, 4/16 of the options shall vest following the lapse of a period of twelve months commencing at the date of grant. The remaining 12/16 of the options shall vest on quarterly basis, so that 1/16 of the options shall vest on the expiry of each quarter. The weighted average grant date fair value per option was $0.89 with exercise price of $1.06. Modification of share-based compensation On November 23, 2022 ("the commencement date"), the Company’s board of directors approved: (1) the cancellation of certain outstanding options granted to employees in September 2019 (which were fully vested), November 2020, January 2021, May 2021 and April 2022, and the grant of a greater number of replacement options thereof under the new terms with a lower exercise price of US $0.57 and a shorter vesting period (except for September 2019's grant). The effect of the modification is discussed in the next paragraph ("the modification") (2) The grant of 21,268 options to a new employee on the same terms of the replacement options granted to the rest of the Company's employees, as described above. As a result of the Modification, (A) 667,641 options were cancelled, comprised of (i) 51,166 options that had been granted in September 2019, at an exercise price of $3.34, (ii) 267,296 options that had been granted in November 2020, at an exercise price of $5.74, (iii) 133,652 options granted in January 2021, at an exercise price of $5.74, and (iv) 51,072 options granted in May 2021, at an exercise price of $3.01, and (ii) 164,455 options that had been granted in April 2022 at an exercise price of $1.06 (the “Cancelled Options”), and (B) 988,773 new options had been granted (including 21,268 option granted to a new employee) (the “New Options”). The New Options vest and become exercisable under the following schedule: 50% of the shares covered by the options are immediately vesting on the commencement date determined by the administrator (and in the absence of such determination, the date on which such options were granted), and 6.25% of the shares covered by the options at the end of each subsequent three-month period thereafter over the course of the following two years. The Modification was considered as a Type I modification. The total incremental fair value of these options amounted to $165. An amount of 50% of the incremental fair value were vested immediately at the commencement date in the amount of $83 were recognized immediately, and the remaining incremental fair value will be recognized over the remaining vesting period through December 31, 2022. In addition, the unrecognized compensation cost as of the date of Modification will be recognized over the vesting period of the new options. As a result, an amount of 50% of the unrecognized compensation cost of the cancelled options were vested immediately in the amount of $454, and the remaining unrecognized compensation cost will be recognized over the remaining vesting period and until December 31, 2022. As of December 31, 2022, the Company had 619,387 unvested options. The total unrecognized compensation cost of employee options as of December 31, 2022 is $1,032. The intrinsic value of share options outstanding as of December 31, 2022 was $9. The intrinsic value of share options exercisable as of December 31, 2022 was $9. 3. The following tables summarizes information about options granted to employees and directors: The 2008 Plan Share options outstanding and exercisable to employees and directors under the 2008 Plan are as follows: Number of options Weighted average exercise price Weighted average remaining contractual life USD Options outstanding at beginning of year 153,882 $ 0.24 2.25 Changes during the year: Options granted - - - Options exercised - - - Options forfeited - - - Options outstanding at end of year 153,882 $ 0.24 1.25 Options exercisable at end of year 153,882 $ 0.24 1.25 The 2019 Plan Share options outstanding and exercisable to employees and directors under the 2019 Plan are as follows: Number of options Weighted average exercise price Weighted average remaining contractual life USD Options outstanding at beginning of year 971,476 $ 4.51 8.72 Changes during the year: 361,280 3.58 8.14 Options granted 1,153,228 0.64 9.82 Options cancelled 667,641 4.19 8.21 Options exercised - - - Options forfeited 117,124 3.34 6.45 Options outstanding at end of year 1,339,939 $ 1.44 9.39 Options exercisable at end of year 720,552 $ 1.50 9.25 4. The following table sets forth the assumptions that were used in determining the fair value of options granted to employees in 2019 plan for the years ended on December 31, 2022 and 2021: 2022* 2021* Expected term 5.28-6.07 5.86-6.11 Risk-free interest rates 2.69%-3.88 % 0.52%-1.13 % Volatility 79.3%-82.6 % 69.67%-78.99 % Dividend yield - - Exercise price $ 0.57-1.06 $ 3.013-5.738 * The assumptions presented above are the original assumptions used to determine the options fair value at the date of the grants. The assumptions used to determine the incremental value of the options at the modification date are as presented at the Company's options valuation. The Company recognized $1,104, $713 and $18 during the years ended December 31, 2022, 2021 and 2020, respectively, as share-based compensation expenses which was included in general and administrative expenses, and $285, $99 and $20 during the years ended December 31, 2022, 2021 and 2020, respectively, as share-based compensation expense which was included in research and development expenses. 5. In August 2020, the Company entered into an IR/PR service agreement (the “Service Agreement”) with Crescendo Communications, LLC (“Crescendo”), for a period of two years, commencing immediately after the IPO closing date, and in consideration for 3.75% of the Company's share capital fully diluted Pre-IPO. On August 23, 2020, the Company's Board of Directors approved the Service Agreement with Crescendo and the grant of 152,110 restricted Company's Ordinary Shares ("the first grant"). The Company recognized $275, $412 and $137 during the year ended December 31, 2022, 2021, and 2020, respectively, as share-based compensation expenses in respect with the first grant. In April 2022 the foregoing shares have been issued. In May 2022, following discussions between the Company and Crescendo regarding the number of shares to which he is entitled, the Company's board of Directors approved the grant of an additional 86,965 of the Company's Ordinary shares, par value NIS 0.03 each to Crescendo ("the second grant"). During 2022 the Company has recognized $67 as share-based compensation expenses in connection with the second grant (Note 10d.4 and note 13).

SELECTED STATEMENTS OF OPERATIO

SELECTED STATEMENTS OF OPERATIONS DATA	12 Months Ended
	Dec. 31, 2022
Disclosure Text Block Supplement [Abstract]
SELECTED STATEMENTS OF OPERATIONS DATA	NOTE 11:- SELECTED STATEMENTS OF OPERATIONS DATA a. Research and development expenses: Year ended December 31, 2022 2021 2020 Subcontractors and consultants $ 2,228 $ 1,654 $ 217 Payroll and related expenses 766 719 90 Share-based compensation expense 285 99 18 Clinical trials expenses 1,121 357 - Other expenses 22 31 29 $ 4,422 $ 2,860 $ 354 b. General and administrative expenses: Year ended December 31, 2022 2021 2020 Professional services $ 1,489 $ 1,697 $ 727 Payroll and related expenses 780 688 154 D&O insurance 653 935 360 Rent and office maintenance 249 210 37 Share-based compensation expense 1,104 713 20 Other expenses 172 105 19 $ 4,447 $ 4,348 $ 1,317 c. Other financial income (expenses), net: Year ended December 31, 2022 2021 2020 Interest income 160 - - Issuance expenses - - (65 ) Bank fees (13 ) (10 ) (3 ) Change in fair value of derivative warrant liability - - (1,105 ) Exchange rate differences $ (61 ) $ (22 ) $ (2 ) Total other financial expenses, net $ 86 $ (32 ) $ (1,175 )

RELATED PARTIES BALANCES AND TR

RELATED PARTIES BALANCES AND TRANSACTIONS	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTIES BALANCES AND TRANSACTIONS	NOTE 12:- RELATED PARTIES BALANCES AND TRANSACTIONS a. During the year ended December 31, 2019 the Company issued convertible notes in the amount of $95, to existing shareholders. As described under Note 6 above, the notes bore interest at an annual interest rate of 8%, compounded on the basis of a 365-day year and were convertible into convertible preferred shares of the Company. b. Starting in January 2014, the Company sub-leased office space and received management services from Zori Medica 2010 Ltd., a private company affiliated with Medica Venture Partners, the controlling shareholder of the Company. The Company was subject to an annual rental fee of $33 for the office space and $20 as a quarterly management fee. The management services continued until the end of March 2018. The sublease ceased as of August 2019, and from then until December 31, 2020 the Company was provided with an office space at no cost by Medica Venture Partners. For the years ended December 31, 2020 and 2019, the Company recorded an amount of $33 and $25, respectively, as a lease expense and a corresponding increase in additional paid-in capital, representing a contribution from its controlling shareholder. As of December 31, 2020, the lease agreement with the related party was terminated. c. On January 26, 2020, the Company’s Board of Directors approved a one-time immediate payment of $150 and a payment of $37.5 on a quarterly basis (for such time as the service engagement continues) to the Chairman of the Board of Directors contingent upon shareholder approval, which was granted on July 6, 2020 and successful completion of Company’s IPO which closed on September 3, 2020. d. On February 23, 2021, the shareholders of the Company approved the grant of options to purchase an aggregate of 300,000 Ordinary Shares to three board members, the Chairman of the board of directors and to its Chief Technology Officer (who also serves as a director). Balances with related parties: Year ended December 31, 2022 2021 2020 Employees accrued salaries and bonuses $ 359 $ 356 $ 79 Directors accrued fees expenses 33 82 35 $ 392 $ 438 $ 114 Transactions with related parties: Year ended December 31, 2022 2021 2020 Amounts charged to: Research and development expenses $ 702 $ 151 $ - General and administrative expenses 2,091 2,155 370 Interest expense on convertible notes $ - $ - $ 251

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13:- SUBSEQUENT EVENTS In February 2023, the Company issued 86,965 Ordinary shares par value NIS 0.03, to Crescendo in connection with the second grant (Note 10d.5 and 10b.4).

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of presentation	a. Basis of presentation: The financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The significant accounting policies described below have been applied consistently in relation to all the periods presented, unless otherwise stated.
Use of estimate in preparation of financial statements	b. Use of estimate in preparation of financial statements: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions. Estimates are primarily used for, but not limited to, valuation of share-based compensation, capitalization of software costs, valuation allowance and uncertain tax positions. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.
Financial statements in United States dollars	c. Financial statements in United States dollars: The Company’s functional currency is the U.S. dollar (“dollar” or “$”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non-U.S. dollar currencies are translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S. dollar transactions and other items in the statements of income (indicated below), the following exchange rates are used: (i) for transactions - exchange rates at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation) - historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses, as appropriate.
Cash and cash equivalents	d. Cash and cash equivalents: Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.
Short term deposit	e. Short term deposit: Bank deposits with original maturity dates of more than three months but at balance sheet date are less than one year are included in short-term deposits. The fair value of bank deposits approximates the carrying value since they bear interest at rates close to the prevailing market rates.
Restricted cash	f. Restricted cash: As of December 31, 2022 and 2021, the Company’s restricted cash consisted of immaterial bank deposits that were denominated in NIS. Restricted deposits are presented at cost including accrued interest. These bank deposits are used as securities for the Company's credit cards.
Fair Value Measurements	g. Fair Value Measurements: The carrying values of Company’s financial assets and liabilities, including cash and cash equivalents, restricted cash, other current assets, trade payables and other accounts payable approximate their fair value due to the short-term maturity of these instruments. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value in the financial statements are categorized as follows: Level 1 Level 2 Level 3 As of December 31, 2022, and 2021 no assets or liabilities are measured in fair value.
Property and equipment, net	h. Property and equipment, net: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers, software and electronic equipment 33 Furniture and office equipment 7
Research and development expenses	i. Research and development expenses: Research and development costs include costs of payroll and related expenses of employees, subcontractors and consultants and other costs related to the Company's operation of its planned clinical trials. Research and development expenses are charged to the statements of comprehensive loss as incurred. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources its clinical trial activities utilizing external entities such as clinical research organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical trials. Clinical trial costs are expensed as incurred.
Employee severance benefits	j. Employee severance benefits: The Company is required to make severance payments upon dismissal of an Israeli employee or upon termination of employment in certain circumstances. In accordance with the current employment terms with all of its employees (Section 14 of the Israeli Severance Pay Law, 1963) located in Israel, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee’s full retirement benefit and severance obligation. The Company is relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected on the Company’s balance sheet, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies. The amounts of severance payment expenses were $60, $58 and $13 for the years ended December 31, 2022, 2021 and 2020, respectively.
Legal and other contingencies	k. Legal and other contingencies: Certain conditions may exist as of the date of the financial statements, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management assesses such contingent liabilities, if any, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. Management applies the guidance in ASC 450-20, “Loss Contingencies” when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be reasonable estimated, then the estimated liability is recorded as accrued expenses in the Company’s financial statements. Legal costs incurred in connection with loss contingencies are expensed as incurred.
Income taxes	l. Income taxes: The Company accounts for income taxes in accordance with ASC 740, “Income Taxes”. ASC 740 prescribes the use of the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all the deferred tax assets will not be realized, based on the weight of available positive and negative evidence. As of December 31, 2022, and 2021, the Company had a full valuation allowance on its deferred tax assets. Deferred tax liabilities and assets are classified as non-current in accordance with ASU 2015‑17. The Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax positions as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement. As of December 31, 2022 and 2021, the total gross amount of provision for unrecognized tax positions was $243 and $234, respectively (Note 7f). The Company recognizes interest and penalties, if any, related to unrecognized tax positions in tax expenses and exchange differences in financial expense.
Concentrations of credit risk	m. Concentrations of credit risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and restricted cash. Cash and cash equivalents and restricted cash are invested in a major bank in Israel and the United States. Management believes that the banks that hold the Company’s cash, cash equivalent and restricted cash are financially sound and, accordingly, minimal credit risk exists with respect to this cash, cash equivalent and restricted cash. The Company relies, and expects to continue to rely, on a single supplier to manufacture supplies and raw materials for its clinical trial. This clinical trial could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.
Convertible notes	n. Convertible notes: Proceeds from the sale of notes with a conversion feature are allocated to equity based on the intrinsic value of such conversion feature (if any) in accordance with ASC 470-20 “Debt with Conversion and Other Options”, with a corresponding discount on the notes recorded in liabilities which is amortized in finance expense over the term of the notes. Convertible notes with convertible features that are determined to not be beneficial are allocated entirely to liabilities.
Derivative warrant liability	o. Derivative warrant liability Financial equity instruments that do not meet the US GAAP criteria for equity classification are classified as a liability at fair value and are adjusted to fair value at each reporting period. Changes in fair value are recognized in the Company’s statements of comprehensive loss in accordance with ASC 815, “Accounting for Derivative Financial Instruments”.
Basic and diluted loss per share	p. Basic and diluted loss per share: Basic loss per share is computed on the basis of the net loss for the period divided by the weighted average number of Ordinary Shares and vested Ordinary Shares issuable for little or no further consideration outstanding during the period. Diluted loss per share is based upon the weighted average number of ordinary shares and of potential Ordinary Shares outstanding when dilutive. Potential Ordinary Shares include outstanding stock options, restricted shares and warrants, which are included under the treasury stock method when dilutive. For the years ended December 31, 2022, 2021 and 2020, all outstanding share options, restricted shares, convertible notes, and warrants have been excluded from the calculation of the diluted net loss per share as all such securities are anti-dilutive for all years presented. The loss and the weighted average number of shares used in computing basic and diluted net loss per share is as follows: Year ended 2022 2021 2020 Numerator: Net loss applicable to shareholders of ordinary shares $ (8,792 ) $ (7,246 ) $ (4,053 ) Denominator: Shares of Ordinary Share and restricted shares used in computing basic and diluted net loss per share 10,661,170 9,812,234 3,243,943 Net loss per share of ordinary share, basic and diluted $ (0.82 ) $ (0.74 ) $ (1.25 )
Share-based compensation	q. Share-based compensation: Share-based compensation to employees and consultants is accounted for in accordance with ASC 718, “Compensation - Share Compensation” (“ASC 718”), which requires estimation of the fair value of share-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service period using the strait line method. The Company has elected to recognize forfeitures, as incurred. The Company grants share (“Share Based Compensation”) to its employees, officers, directors, and non-employees in consideration for services rendered (Note 10). The Company accounts for Share-Based Compensation awards classified as equity awards using the grant-date fair value method. The fair value at grant-date of the issued equity award is recognized as an expense on a straight-line basis over the requisite service period. The fair value of each share option granted is estimated using the Black-Scholes option pricing model, which requires a number of assumptions, of which the most significant are the expected share price, volatility, and the expected option term. Expected volatility was calculated based on comparable public companies in the same industry. The expected share option term is calculated for share options granted using the “simplified” method when the required conditions are met. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The expected dividend yield assumption is based on the Company’s historical experience and expectation of no future dividend pay outs. The Company has historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future. The Company elected to recognize Share-Based Compensation cost for awards with only service conditions that have a graded vesting schedule using the straight-line method based on the multiple-option award approach.
Deferred offering costs	r. Deferred offering costs The Company capitalizes certain legal and other third-party fees that are directly related to the Company’s in-process equity financings until such financings are consummated. After the consummation of such equity financings, these costs are recorded as a reduction of the respective gross proceeds. Should a planned equity financing be abandoned, terminated, or significantly delayed, the deferred offering costs are written off to operating expenses. As of December 31, 2022 and 2021, there were no deferred offering costs.
Segment Reporting	s. Segment Reporting The Company has one operating and reportable segment. An operating segment is defined as a component that engages in business activities whose operating results are reviewed by the chief operating decision maker, who is the Company’s Chief Executive Officer, for the purpose of assessing performance and allocating resources and for which discrete financial information is available.
Leases	t. Leases In accordance with Accounting Standards Codification (“ASC”) 842, Leases, the Company determines whether an arrangement is or contains a lease at the inception of the arrangement and whether such a lease is classified as a financing lease or operating lease at the commencement date of the lease. The Company elected not to recognize the right-of-use assets and lease liabilities for short-term leases which it defines as leases with lease terms. The company defines a short-term lease if a lease has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. All of the Company's leases are classified as short-term. Lease expense for lease payments is recognized on a straight-line basis over the lease term in general and administrative (Note 8a).
Recently adopted accounting pronouncement	u. Recently adopted accounting pronouncement In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. The Company adopted ASU 2020-06 on January 1, 2022 and it did not have a material impact on the Company’s financial statements and disclosures.
Recently Issued Accounting Pronouncements Not Yet Adopted	v. Recently Issued Accounting Pronouncements Not Yet Adopted Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of depreciation rates for property and equipment	% Computers, software and electronic equipment 33 Furniture and office equipment 7
Schedule of computation of basic and diluted losses per share	Year ended 2022 2021 2020 Numerator: Net loss applicable to shareholders of ordinary shares $ (8,792 ) $ (7,246 ) $ (4,053 ) Denominator: Shares of Ordinary Share and restricted shares used in computing basic and diluted net loss per share 10,661,170 9,812,234 3,243,943 Net loss per share of ordinary share, basic and diluted $ (0.82 ) $ (0.74 ) $ (1.25 )

PREPAID EXPENSES AND OTHER CU_2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of prepaid expenses and other current assets	December 31, 2022 2021 Receivables from governmental authorities $ 55 $ 218 Prepaid expenses 310 473 Other - 30 $ 365 $ 721

ACCURUED EXPENSES (Tables)

ACCURUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2022
Accrued Liabilities [Abstract]
Schedule of accrued expenses	December 31, 2022 2021 Directors’ fees $ 33 $ 46 Manufacturing expenses 168 13 Advisors and legal expenses 155 139 $ 356 $ 198

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of significant unobservable inputs (Level 3 inputs) used in measuring the warrants	September 3, December 31 2020 2019 Exercise price $ 6.72-$8.80 $ 2.55-$4.74 Expected volatility 72.29 % 72.29 % Risk free rate 0.22 % 1.5-1.67 % Expected life (years) 3.98-5 4.65-5 Dividend yield - -

TAXES ON INCOME (Tables)

TAXES ON INCOME (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of deferred income taxes	December 31, 2022 2021 Net operating loss carry forward $ 4,530 $ 4,434 Research and development expenses 812 463 Other 34 21 Less: Valuation allowance (5,376 ) (4,918 ) Net deferred tax asset $ - $ -
Schedule of unrecognized tax benefits	December 31, 2022 2021 2020 Opening balance $ 234 $ 220 $ - Tax positions taken in the current year - 217 Interest and Exchange difference 9 14 3 Closing balance $ 243 $ 234 $ 220

TEMPORARY EQUITY (Tables)

TEMPORARY EQUITY (Tables)	12 Months Ended
	Dec. 31, 2022
Temporary Equity Disclosure [Abstract]
Schedule of convertible preferred shares	Convertible preferred shares consisted of the following: Convertible Preferred Shares - Series A Shares Shares Carrying Liquidation As of December 31, 2019 18,300,000 2,954,267 $ 6,621 $ 15,250

SHAREHOLDERS' EQUITY (Tables)

SHAREHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of warrants and warrants units outstanding	Type Issuance Date Number of warrants Exercise price Exercisable through August 2019 warrants August 22, 2019 205,268 $6.72 (*) August 22, 2024 December 2019 warrants December 9, 2019 148,106 $6.72 (*) December 8, 2024 Warrants to underwriters September 3, 2020 125,000 $10.00 September 1, 2025 Warrants to underwriters October 5, 2020 375,000 $8.80 September 3, 2025 IPO warrants September 3, 2020 2,812,170 $8.80 September 3, 2025 PIPE warrants March 11, 2021 232,500 $4.60 September 10, 2026 Warrants to PIPE placement agent March 11,2021 52,173 $5.06 March 8, 2026 TOTAL 3,950,217 (*) Each warrant is exercisable into one IPO unit consisting of one share and one IPO warrant with an exercise price of $8.80.
Schedule of Black-Scholes to estimate fair value	2022* 2021* Expected term 5.28-6.07 5.86-6.11 Risk-free interest rates 2.69%-3.88 % 0.52%-1.13 % Volatility 79.3%-82.6 % 69.67%-78.99 % Dividend yield - - Exercise price $ 0.57-1.06 $ 3.013-5.738
Plan Twenty Thousand Nineteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of share options outstanding and exercisable to employees and directors	Number of options Weighted average exercise price Weighted average remaining contractual life USD Options outstanding at beginning of year 971,476 $ 4.51 8.72 Changes during the year: 361,280 3.58 8.14 Options granted 1,153,228 0.64 9.82 Options cancelled 667,641 4.19 8.21 Options exercised - - - Options forfeited 117,124 3.34 6.45 Options outstanding at end of year 1,339,939 $ 1.44 9.39 Options exercisable at end of year 720,552 $ 1.50 9.25
2008 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of share options outstanding and exercisable to employees and directors	Number of options Weighted average exercise price Weighted average remaining contractual life USD Options outstanding at beginning of year 153,882 $ 0.24 2.25 Changes during the year: Options granted - - - Options exercised - - - Options forfeited - - - Options outstanding at end of year 153,882 $ 0.24 1.25 Options exercisable at end of year 153,882 $ 0.24 1.25

SELECTED STATEMENTS OF OPERAT_2

SELECTED STATEMENTS OF OPERATIONS DATA (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure Text Block Supplement [Abstract]
Schedule of research and development expenses	Year ended December 31, 2022 2021 2020 Subcontractors and consultants $ 2,228 $ 1,654 $ 217 Payroll and related expenses 766 719 90 Share-based compensation expense 285 99 18 Clinical trials expenses 1,121 357 - Other expenses 22 31 29 $ 4,422 $ 2,860 $ 354
Schedule of general and administrative expenses	Year ended December 31, 2022 2021 2020 Professional services $ 1,489 $ 1,697 $ 727 Payroll and related expenses 780 688 154 D&O insurance 653 935 360 Rent and office maintenance 249 210 37 Share-based compensation expense 1,104 713 20 Other expenses 172 105 19 $ 4,447 $ 4,348 $ 1,317
Schedule of financial expenses net	Year ended December 31, 2022 2021 2020 Interest income 160 - - Issuance expenses - - (65 ) Bank fees (13 ) (10 ) (3 ) Change in fair value of derivative warrant liability - - (1,105 ) Exchange rate differences $ (61 ) $ (22 ) $ (2 ) Total other financial expenses, net $ 86 $ (32 ) $ (1,175 )

RELATED PARTIES BALANCES AND _2

RELATED PARTIES BALANCES AND TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Schedule of balances and transactions with related parties	Balances with related parties: Year ended December 31, 2022 2021 2020 Employees accrued salaries and bonuses $ 359 $ 356 $ 79 Directors accrued fees expenses 33 82 35 $ 392 $ 438 $ 114 Transactions with related parties: Year ended December 31, 2022 2021 2020 Amounts charged to: Research and development expenses $ 702 $ 151 $ - General and administrative expenses 2,091 2,155 370 Interest expense on convertible notes $ - $ - $ 251

GENERAL (Narrative) (Details)

GENERAL (Narrative) (Details) $ / shares in Units, $ in Thousands

1 Months Ended

12 Months Ended

Mar. 11, 2021 USD ($) shares

Oct. 05, 2020 USD ($) shares

Sep. 03, 2020 $ / shares shares

Jul. 06, 2020

Jul. 22, 2021 USD ($) shares

Dec. 31, 2022 USD ($) $ / shares shares

Dec. 31, 2021 USD ($)

Dec. 31, 2020 USD ($)

Feb. 28, 2023 ₪ / shares shares

Apr. 30, 2022 shares

Mar. 11, 2021 ₪ / shares shares

Mar. 11, 2021 $ / shares shares

Dec. 31, 2019 $ / shares

Aug. 31, 2019 $ / shares

Subsidiary, Sale of Stock [Line Items]

Net loss

$ (8,792)

$ (7,246)

$ (4,053)

Accumulated deficit

(32,519)

(23,727)

Cash

10,191

Reverse split

1-for-3 reverse split

Proceeds from exercise of warrants

$ 1,930

$ 0

1,930

0

Number of ordinary shares called by warrants | shares

419,673

3,950,217

Warrants Issued to purchase aggregate ordinary shares | shares

52,173

Warrants exercise price | $ / shares

$ 5.06

$ 100

$ 100

Share-based compensation to employees

$ 1,389

812

38

Cash used in operating activities

$ (6,459)

$ (6,553)

$ (2,557)

Subsequent Event [Member]

Subsidiary, Sale of Stock [Line Items]

Ordinary shares issued | shares

86,965

Original issue price per share | ₪ / shares

₪ 0.03

Private Placement [Member]

Subsidiary, Sale of Stock [Line Items]

Gross proceeds from issuance of warrants

$ 6,000

Number of ordinary shares called by warrants | shares

1,304,346

1,304,346

Warrants Issued to purchase aggregate ordinary shares | shares

652,173

Combined purchase price | (per share)

₪ 0.03

$ 4.6

Proceeds from issuance of private placement

$ 5,554

Warrants exercise price | $ / shares

$ 4.6

IPO [Member]

Subsidiary, Sale of Stock [Line Items]

Ordinary shares issued | shares

2,500,000

Original issue price per share | $ / shares

$ 8

Warrants expired

5 years

Warrants exercise price | $ / shares

$ 8.8

$ 8.8

Over-Allotment Option [Member]

Subsidiary, Sale of Stock [Line Items]

Gross proceeds from issuance of warrants

$ 20,000

Net proceeds after deducting underwriting discounts and commissions

$ 17,300

Number of ordinary shares called by warrants | shares

375,000

Proceeds from issuance of private placement

$ 3,000

2019 Plan [Member] | Board Of Director [Member]

Subsidiary, Sale of Stock [Line Items]

Ordinary shares issued | shares

1,000,000

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Unrecognized tax	$ 243	$ 234	$ 220	$ 0

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)	12 Months Ended
	Dec. 31, 2022
Computers, software and electronic equipment [Member]
Property, Plant and Equipment [Line Items]
Annual depreciation rate	33%
Furniture and office equipment [Member]
Property, Plant and Equipment [Line Items]
Annual depreciation rate	7%

SIGNIFICANT ACCOUNTING POLICI_6

SIGNIFICANT ACCOUNTING POLICIES (Schedule of Computation of Basic and Diluted Losses Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Numerator:
Net loss applicable to shareholders of ordinary shares	$ (8,792)	$ (7,246)	$ (4,053)
Denominator:
Shares of ordinary share and restricted shares used in computing basic net loss per share	10,661,170	9,812,234	3,243,943
Shares of ordinary share and restricted shares used in computing diluted net loss per share	10,661,170	9,812,234	3,243,943
Basic and diluted net loss per share basic (in dollars per share)	$ (0.82)	$ (0.74)	$ (1.25)
Basic and diluted net loss per share diluted (in dollars per share)	$ (0.82)	$ (0.74)	$ (1.25)

PREPAID EXPENSES AND OTHER CU_3

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Schedule of Prepaid Expenses and Other Current Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Receivables from governmental authorities	$ 55	$ 218
Prepaid expenses	310	473
Other	0	30
Total prepaid expenses and other current assets	$ 365	$ 721

ACCURUED EXPENSES (Details)

ACCURUED EXPENSES (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accrued Liabilities [Abstract]
Directors’ fees	$ 33	$ 46
Manufacturing expenses	168	13
Advisors and legal expenses	155	139
ACCURUED EXPENSES	$ 356	$ 198

FAIR VALUE MEASUREMENTS (Schedu

FAIR VALUE MEASUREMENTS (Schedule of significant unobservable inputs (Level 3 inputs) used in measuring the warrants) (Details) - $ / shares	8 Months Ended	12 Months Ended
	Sep. 03, 2020	Dec. 31, 2019	Apr. 30, 2022
Defined Benefit Plan, Plan Assets, Level 3 Reconciliation [Line Items]
Exercise price (in dollars per share)			$ 1.06
Level 3 inputs [Member]
Defined Benefit Plan, Plan Assets, Level 3 Reconciliation [Line Items]
Expected volatility	72.29%	72.29%
Risk free rate	0.22%
Dividend yield	0%	0%
Level 3 inputs [Member] | Minimum [Member]
Defined Benefit Plan, Plan Assets, Level 3 Reconciliation [Line Items]
Exercise price (in dollars per share)	$ 6.72	$ 2.55
Risk free rate		1.50%
Expected life (years)	3 years 11 months 23 days	4 years 7 months 24 days
Level 3 inputs [Member] | Maximum [Member]
Defined Benefit Plan, Plan Assets, Level 3 Reconciliation [Line Items]
Exercise price (in dollars per share)	$ 8.8	$ 4.74
Risk free rate		1.67%
Expected life (years)	5 years	5 years

CONVERTIBLE NOTES (Narrative) (

CONVERTIBLE NOTES (Narrative) (Details) $ / shares in Units, $ in Thousands			1 Months Ended		12 Months Ended
	Sep. 03, 2020 $ / shares shares	Dec. 09, 2019 $ / shares shares	Dec. 31, 2019 USD ($) $ / shares	Aug. 31, 2019 USD ($) $ / shares	Dec. 31, 2022 $ / shares shares	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($) $ / shares
Convertible Notes (Details) [Line Items]
Convertible notes | $			$ 4,417				$ 4,417
Interest expense | $						$ 271	379
Convertible notes issued (in Shares) | shares					2,415,022
Convertible notes (units)			14.2	14.2
Convertible notes and warrants total consideration | $			$ 1,420	$ 1,420			$ 1,420
Convertible notes and warrants consideration per unit (in Dollars per share)			$ 100	$ 100	$ 5.06		$ 100
Discount of warrant			10%	10%
Financing expense | $						$ 65
Convertible Notes Related Warrants 2019 [Member]
Convertible Notes (Details) [Line Items]
Convertible notes and warrants consideration per unit (in Dollars per share)		$ 8.8
Warrant exercise price per unit		$ 6.72
Ordinary Shares issued | shares		55,785
Warrant expired		Dec. 08, 2024
IPO [Member]
Convertible Notes (Details) [Line Items]
Convertible notes issued (in Shares) | shares	312,170
Convertible notes and warrants consideration per unit (in Dollars per share)	$ 8.8				$ 8.8
Warrant term	5 years
Ordinary Shares issued | shares	2,500,000
IPO [Member] | Convertible Notes Related Warrants 2019 [Member]
Convertible Notes (Details) [Line Items]
Convertible notes and warrants consideration per unit (in Dollars per share)	$ 6.72
Convertible debt conversion price (in Dollars per share)	$ 8.8
Warrant excercise | shares	297,589

TAXES ON INCOME (Narrative) (De

TAXES ON INCOME (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Tax Credit Carryforward [Line Items]
Corporate tax rate	23%	23%	23%
Provision for unrecognized tax positions	$ 243	$ 234	$ 220	$ 0
Interest and Exchange difference	9	14	$ 3
Israeli [Member]
Tax Credit Carryforward [Line Items]
Net operating loss carry forwards	$ 19,695	$ 19,261

TAXES ON INCOME (Schedule of De

TAXES ON INCOME (Schedule of Deferred Income Taxes) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating loss carry forward	$ 4,530	$ 4,434
Research and development expenses	812	463
Other	34	21
Less: Valuation allowance	(5,376)	(4,918)
Net deferred tax asset	$ 0	$ 0

TAXES ON INCOME (Schedule of Un

TAXES ON INCOME (Schedule of Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Opening balance	$ 234	$ 220	$ 0
Tax positions taken in the current year		0	217
Interest and Exchange difference	9	14	3
Closing balance	$ 243	$ 234	$ 220

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($) $ in Thousands		12 Months Ended
	Dec. 03, 2020	Dec. 31, 2022	Dec. 31, 2021	Jul. 26, 2021	Dec. 31, 2020	Dec. 10, 2020
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Annual rental fee		$ 33		$ 68	$ 33	$ 20
Prepaid clinical trial expenses and deferred clinical trial costs		1,728	$ 1,728
Clinical trial expense		1,110	145
Amount of Milestone completion payment		5,568
Milestone payment for actual number of evaluable		8,636
First Agreement [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Accumulated payment on clinical research development	$ 2,907
Second Agreement [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Accumulated payment on clinical research development	$ 7,107
Non refundable payment of clinical research and development.		$ 1,728	$ 1,728

TEMPORARY EQUITY (Narrative) (D

TEMPORARY EQUITY (Narrative) (Details)	Sep. 03, 2020 shares
Temporary Equity Disclosure [Abstract]
Outstanding convertible preferred shares	2,954,267

TEMPORARY EQUITY (Schedule of C

TEMPORARY EQUITY (Schedule of Convertible Preferred Shares) (Details) $ in Thousands	Dec. 31, 2019 USD ($) shares
Temporary Equity Disclosure [Abstract]
Shares Authorized | shares	18,300,000
Shares Issued and Outstanding | shares	2,954,267
Carrying Value | $	$ 6,621
Liquidation Preference | $	$ 15,250

SHAREHOLDERS' EQUITY (Narrative

SHAREHOLDERS' EQUITY (Narrative) (Details) $ / shares in Units, $ in Thousands						1 Months Ended									12 Months Ended
	Mar. 11, 2021 USD ($) shares	Oct. 05, 2020 USD ($) $ / shares shares	Sep. 03, 2020 $ / shares shares	Jul. 06, 2020	Sep. 30, 2019 shares	Nov. 23, 2022 $ / shares	May 31, 2022 USD ($)	Apr. 30, 2022 $ / shares shares	Jul. 22, 2021 USD ($) shares	May 31, 2021 $ / shares shares	Feb. 23, 2021 $ / shares shares	Jan. 31, 2021 $ / shares shares	Nov. 30, 2020 $ / shares shares	Sep. 30, 2019 $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2022 ₪ / shares	Dec. 31, 2022 USD ($) $ / shares shares	May 31, 2022 ₪ / shares shares	Dec. 31, 2021 ₪ / shares shares	Mar. 11, 2021 ₪ / shares shares	Mar. 11, 2021 $ / shares shares	Oct. 03, 2020 $ / shares	Aug. 31, 2020 shares	Dec. 31, 2019 $ / shares	Dec. 09, 2019 $ / shares	Aug. 31, 2019 $ / shares	Jul. 02, 2019 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary share issued								152,110											10,634,166		10,482,056
Reverse split				3-for-1
Convertible notes issued (in Shares)															2,415,022
Warrants exercise price | $ / shares																			$ 5.06							$ 100		$ 100
Outstanding convertible preferred shares			2,954,267
Options granted					51,166			164,455		51,072	300,000	133,652	267,296		988,773
Per share price | (per share)											$ 4.5							₪ 0.03			₪ 0.03
Share-based compensation expense | $															$ 285	$ 99	$ 18
Intrinsic value of share options outstanding | $																			$ 9
Intrinsic value of share options exercisable | $																			$ 9
Warrants Issued to purchase aggregate ordinary shares															52,173
Number of ordinary shares called by warrants									419,673										3,950,217
Proceeds from exercise of warrants | $									$ 1,930						$ 0	1,930	0
Placement agent fees and other expense | $															500
Private placement fee | $															390
Reimbursement Expense | $															$ 40
Lower exercise price | $ / shares						$ 0.57
Cancelled					667,641
Stock option share percentage granted															6.25%
Incremental Fair Value Of Stock Options | $															$ 165
Percentage of incremental fair value vested															50%
Percentage Of Unrecognized Compensation Cost															50%
Unrecognized compensation cost | $																			$ 454
Number of unvested stock options															619,387
Vested Incremental Fair Value Of Stock Options | $															$ 83
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $															1,104	713	18
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $															$ 285	99	20
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted											60,000
2008 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term plan															excess of 10 years
Options outstanding																			153,882		153,882
Options granted								164,455		51,072		133,652	267,296	51,166	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period															0
Intrinsic value of share options outstanding | $																			$ 27
Weighted average exercise price of options granted | $ / shares								$ 1.06		$ 3.01		$ 5.74	$ 5.74	$ 3.34	$ 0
Cancelled														667,641
2019 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reserve for issuance																													971,476
Options outstanding																			1,339,939		971,476
Options granted															1,153,228
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period															117,124
Number of options approved for grant								164,455
Vesting period of options								4 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights								4/16 of the options shall vest following the lapse of a period of twelve months commencing at the date of grant. The remaining 12/16 of the options shall vest on quarterly basis, so that 1/16 of the options shall vest on the expiry of each quarter.
Weighted average grant date fair value per option | $ / shares								$ 0.89
Weighted average exercise price of options granted | $ / shares								$ 1.06							$ 0.64
Cancelled															667,641
Percentage Of Unrecognized Compensation Cost															50%
Unrecognized compensation cost | $																			$ 454
Convertible Notes Related Warrants 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares																											$ 8.8
IPO [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Convertible notes issued (in Shares)			312,170
Warrants Expired			5 years
Warrants exercise price | $ / shares			$ 8.8																$ 8.8
IPO [Member] | Convertible Notes Related Warrants 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares			$ 6.72
Warrant excercise			297,589
Over-Allotment Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant excercise			375,000
Per share price | $ / shares			$ 0.01
Number of ordinary shares called by warrants		375,000
Proceeds from issuance of private placement | $		$ 3,000
Private Placement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares																							$ 4.6
Warrants Issued to purchase aggregate ordinary shares	652,173
Number of ordinary shares called by warrants																						1,304,346	1,304,346
Gross proceeds from issuance of private placement | $	$ 6,000
Proceeds from issuance of private placement | $	$ 5,554
Combined purchase price | (per share)																						₪ 0.03	$ 4.6
Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted															21,268
Unrecognized compensation cost | $																			$ 1,032
New Option [Member] | 2008 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted														988,773
New Option [Member] | 2008 Plan [Member] | Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted														21,268
Crescendo Communications [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary share issued																				86,965
Per share price | ₪ / shares																				₪ 0.03
Share-based compensation expense | $							$ 67
Crescendo Communications [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary share issued																									152,110
Percentage of shares issued																									3.75%
Share-based compensation expense | $															$ 275	$ 412	$ 137
Underwriters [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares		$ 8.8
Warrant excercise		375,000
Warrant expired date		Sep. 03, 2025
Amount of return | $		$ 3
Underwriters [Member] | IPO [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Expired			5 years
Options granted			125,000
Per share price | $ / shares			$ 10																					$ 10
Offering price			125%

SHAREHOLDERS' EQUITY (Schedule

SHAREHOLDERS' EQUITY (Schedule of Warrants and Warrants Units Outstanding) (Details) - $ / shares		12 Months Ended
		Dec. 31, 2022	Jul. 22, 2021	Dec. 31, 2019	Aug. 31, 2019
Class of Warrant or Right [Line Items]
Number of warrants		3,950,217	419,673
Exercise price		$ 5.06		$ 100	$ 100
August 2019 warrants [Member]
Class of Warrant or Right [Line Items]
Issuance Date		Aug. 22, 2019
Number of warrants		205,268
Exercise price	[1]	$ 6.72
Exercisable through		Aug. 22, 2024
December 2019 warrants [Member]
Class of Warrant or Right [Line Items]
Issuance Date		Dec. 09, 2019
Number of warrants		148,106
Exercise price	[1]	$ 6.72
Exercisable through		Dec. 08, 2024
Warrants to underwriters [Member]
Class of Warrant or Right [Line Items]
Issuance Date		Sep. 03, 2020
Number of warrants		125,000
Exercise price		$ 10
Exercisable through		Sep. 01, 2025
Warrants To Underwriters [Member]
Class of Warrant or Right [Line Items]
Issuance Date		Oct. 05, 2020
Number of warrants		375,000
Exercise price		$ 8.8
Exercisable through		Sep. 03, 2025
IPO warrants [Member]
Class of Warrant or Right [Line Items]
Issuance Date		Sep. 03, 2020
Number of warrants		2,812,170
Exercise price		$ 8.8
Exercisable through		Sep. 03, 2025
PIPE warrants [Member]
Class of Warrant or Right [Line Items]
Issuance Date		Mar. 11, 2021
Number of warrants		232,500
Exercise price		$ 4.6
Exercisable through		Sep. 10, 2026
Warrants to PIPE placement agent [Member]
Class of Warrant or Right [Line Items]
Issuance Date		Mar. 11, 2021
Number of warrants		52,173
Exercise price		$ 5.06
Exercisable through		Mar. 08, 2026
[1]Each warrant is exercisable into one IPO unit consisting of one share and one IPO warrant with an exercise price of $8.80.

SHAREHOLDERS' EQUITY (Schedul_2

SHAREHOLDERS' EQUITY (Schedule of share options outstanding and exercisable under 2008 Plan) (Details) - $ / shares		1 Months Ended						12 Months Ended
	Sep. 30, 2019	Apr. 30, 2022	May 31, 2021	Feb. 23, 2021	Jan. 31, 2021	Nov. 30, 2020	Sep. 30, 2019	Dec. 31, 2022	Dec. 31, 2021
Number of options
Granted	51,166	164,455	51,072	300,000	133,652	267,296		988,773
2008 Plan [Member]
Number of options
Options outstanding								153,882
Granted		164,455	51,072		133,652	267,296	51,166	0
Exercised								0
Forfeited								0
Options outstanding								153,882	153,882
Exercisable at the end of the year								153,882
Weighted-average exercise price
Outstanding at the beginning of the year								$ 0.24
Granted		$ 1.06	$ 3.01		$ 5.74	$ 5.74	$ 3.34	0
Exercised								0
Forfeited								0
Outstanding at the end of the year								0.24	$ 0.24
Exercisable at the end of the year								$ 0.24
Weighted-average remaining contractual term
Outstanding at the beginning of the year								1 year 3 months	2 years 3 months
Exercisable at the end of the year								1 year 3 months

SHAREHOLDERS' EQUITY (Schedul_3

SHAREHOLDERS' EQUITY (Schedule of Stock Option Activity) (Details) - $ / shares		1 Months Ended					12 Months Ended
	Sep. 30, 2019	Apr. 30, 2022	May 31, 2021	Feb. 23, 2021	Jan. 31, 2021	Nov. 30, 2020	Dec. 31, 2022	Dec. 31, 2021
Number of options
Granted	51,166	164,455	51,072	300,000	133,652	267,296	988,773
Cancelled	667,641
2019 Plan [Member]
Number of options
Options outstanding							971,476
Changes during the year							361,280
Granted							1,153,228
Forfeited							117,124
Cancelled							667,641
Exercised							0
Options outstanding							1,339,939	971,476
Exercisable at the end of the year							720,552
Weighted-average exercise price
Outstanding at the beginning of the year							$ 4.51
Changes during the year							3.58
Granted		$ 1.06					0.64
Cancelled							4.19
Forfeited	$ 3.34						3.34
Exercised							0
Outstanding at the end of the year							1.44	$ 4.51
Exercisable at the end of the year							$ 1.5
Weighted-average remaining contractual term
Outstanding at the beginning of the year							9 years 4 months 20 days	8 years 8 months 19 days
Changes during the year							8 years 1 month 20 days
Granted							9 years 9 months 25 days
Cancelled							8 years 2 months 15 days
Forfeited							6 years 5 months 12 days
Exercisable at the end of the year							9 years 3 months

SHAREHOLDERS' EQUITY (Schedul_4

SHAREHOLDERS' EQUITY (Schedule of assumptions used for fair value of options) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022		Dec. 31, 2021	Apr. 30, 2022	May 31, 2021	Jan. 31, 2021	Nov. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price				$ 1.06
2019 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0%		0%
Exercise price					$ 3.01	$ 5.74	$ 5.74
Minimum [Member] | 2019 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	5 years 3 months 10 days	[1]	5 years 10 months 9 days
Risk-free interest rates	2.69%	[1]	0.52%
Volatility	79.30%	[1]	69.67%
Exercise price	$ 0.57	[1]	$ 3.013
Maximum [Member] | 2019 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	6 years 25 days	[1]	6 years 1 month 9 days
Risk-free interest rates	3.88%	[1]	1.13%
Volatility	82.60%	[1]	78.99%
Exercise price	$ 1.06	[1]	$ 5.738
[1]The assumptions presented above are the original assumptions used to determine the options fair value at the date of the grants. The assumptions used to determine the incremental value of the options at the modification date are as presented at the Company's options valuation.

SELECTED STATEMENTS OF OPERAT_3

SELECTED STATEMENTS OF OPERATIONS DATA (Schedule of Research and Development Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Financial Expenses Net [Abstract]
Subcontractors and consultants	$ 2,228	$ 1,654	$ 217
Payroll and related expenses	766	719	90
Share-based compensation expense	285	99	18
Clinical trials expenses	1,121	357	0
Other expenses	22	31	29
Total Research and development expenses	$ 4,422	$ 2,860	$ 354

SELECTED STATEMENTS OF OPERAT_4

SELECTED STATEMENTS OF OPERATIONS DATA (Schedule of General and Administrative Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Financial Expenses Net [Abstract]
Professional services	$ 1,489	$ 1,697	$ 727
Payroll and related expenses	780	688	154
D&O insurance	653	935	360
Rent and office maintenance	249	210	37
Share-based compensation expense	1,104	713	20
Other expenses	172	105	19
Total General and administrative expenses	$ 4,447	$ 4,348	$ 1,317

SELECTED STATEMENTS OF OPERAT_5

SELECTED STATEMENTS OF OPERATIONS DATA (Schedule of Financial Expenses, Net) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Financial Expenses Net [Abstract]
Interest income	$ 160	$ 0	$ 0
Issuance expenses	0	0	(65)
Bank fees	(13)	(10)	(3)
Change in fair value of derivative warrant liability	0	0	(1,105)
Exchange rate differences	(61)	(22)	(2)
Total other financial expenses, net	$ 86	$ (32)	$ (1,175)

RELATED PARTIES BALANCES AND _3

RELATED PARTIES BALANCES AND TRANSACTIONS (Details) - USD ($)

1 Months Ended

12 Months Ended

Sep. 30, 2019

Apr. 30, 2022

May 31, 2021

Feb. 23, 2021

Jan. 31, 2021

Nov. 30, 2020

Jan. 26, 2020

Dec. 31, 2022

Dec. 31, 2020

Dec. 31, 2019

Jul. 26, 2021

Dec. 10, 2020

Related Party Transaction [Line Items]

Convertible notes

$ 4,417,000

Rental properties

$ 33,000

$ 33,000

$ 68,000

$ 20,000

Management fee

$ 20,000

Operating lease provided by controlling shareholder

33,000

Options granted

51,166

164,455

51,072

300,000

133,652

267,296

988,773

Additional Paid-in Capital [Member]

Related Party Transaction [Line Items]

Operating lease provided by controlling shareholder

$ 33,000

25,000

Director [Member]

Related Party Transaction [Line Items]

One time payment

$ 150,000

Board of Directors Chairman [Member]

Related Party Transaction [Line Items]

One time payment, quarterly basis

$ 37,500

Chief Executive Officer [Member]

Related Party Transaction [Line Items]

Options granted

60,000

Three board members, Chairman of the board of directors and to its Chief Technology Officer [Member]

Related Party Transaction [Line Items]

Options granted

300,000

Shareholder [Member]

Related Party Transaction [Line Items]

Convertible notes

$ 95,000

Convertible notes annual interest rate

8%

RELATED PARTIES BALANCES AND _4

RELATED PARTIES BALANCES AND TRANSACTION ( Schedule of Balances and Transactions with Related Parties ) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Related Party Transactions [Abstract]
Employees accrued salaries and bonuses	$ 359	$ 356	$ 79
Directors accrued fees expenses	33	82	35
Employees and directors expense	$ 392	$ 438	$ 114

RELATED PARTIES BALANCES AND _5

RELATED PARTIES BALANCES AND TRANSACTIONS (Schedule of Balances and Transactions with Related Parties) (Details1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Amounts charged to
Research and development expenses	$ 702	$ 151	$ 0
General and administrative expenses	2,091	2,155	370
Interest expense on convertible notes	$ 0	$ 0	$ 251

SUBSEQUENT EVENTS (Narrative) (

SUBSEQUENT EVENTS (Narrative) (Details) - Subsequent Event [Member]	Feb. 28, 2023 ₪ / shares shares
Subsequent Event [Line Items]
Ordinary shares issued | shares	86,965
Share price per unit (in Dollars per share) | ₪ / shares	₪ 0.03